Value of F-18 FDG PET/CT for the Prediction of EGFR Mutation in Lung Cancer Patients
1 other identifier
observational
60
0 countries
N/A
Brief Summary
To detect value of F-18FDG PET/CT as a non-invasive method for the prediction of EGFR mutations in lung cancer patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Oct 2024
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 20, 2024
CompletedFirst Posted
Study publicly available on registry
July 25, 2024
CompletedStudy Start
First participant enrolled
October 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
October 1, 2028
July 25, 2024
July 1, 2024
4 years
July 20, 2024
July 24, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
• Assessment of semi-quantitative F-18 FDG PET/CT as a non-invasive method for prediction of EGFR mutations in lung cancer patients.
detection value of F-18 FDG PET/CT for the prediction of EGFR mutation in lung cancer patients.
baseline
Secondary Outcomes (1)
• Assessment of the relationship between degree of the tracer uptake and pathology of the lesion.
baseline
Interventions
F-18 FDGPET/CT oncology protocol for lung cancer patients
Eligibility Criteria
All patients with NSCLC who are ≥ 18 years and underwent EGFR mutation testing and not treated before F-18FDG PET/CT study.
You may qualify if:
- NSCLC patients who underwent EGFR mutation testing.
- All patients ≥ 18 years.
You may not qualify if:
- Time interval between EGFR sampling and PET/CT more than 1 month.
- Patients had been treated before sampling for the gene alteration analysis
- Patients with glucose level \< 200 mg/dl.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (4)
Bade BC, Dela Cruz CS. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin Chest Med. 2020 Mar;41(1):1-24. doi: 10.1016/j.ccm.2019.10.001.
PMID: 32008623BACKGROUNDHarrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 2020 Apr;61:167-179. doi: 10.1016/j.semcancer.2019.09.015. Epub 2019 Sep 25.
PMID: 31562956BACKGROUNDLv Z, Fan J, Xu J, Wu F, Huang Q, Guo M, Liao T, Liu S, Lan X, Liao S, Geng W, Jin Y. Value of 18F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients. Eur J Nucl Med Mol Imaging. 2018 May;45(5):735-750. doi: 10.1007/s00259-017-3885-z. Epub 2017 Nov 21.
PMID: 29164298BACKGROUNDHuang CT, Yen RF, Cheng MF, Hsu YC, Wei PF, Tsai YJ, Tsai MF, Shih JY, Yang CH, Yang PC. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. Med Oncol. 2010 Mar;27(1):9-15. doi: 10.1007/s12032-008-9160-1. Epub 2009 Jan 7.
PMID: 19130320BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant lecturer
Study Record Dates
First Submitted
July 20, 2024
First Posted
July 25, 2024
Study Start
October 1, 2024
Primary Completion (Estimated)
October 1, 2028
Study Completion (Estimated)
October 1, 2028
Last Updated
July 25, 2024
Record last verified: 2024-07